FDA approves a 500-mg dose of AstraZeneca's cancer drug Faslodex

09/13/2010 | Drug Store News

AstraZeneca obtained FDA approval for a 500-milligram dose of Faslodex, an injectable treatment for metastatic breast cancer in postmenopausal women who received anti-estrogen therapy. The strength replaces a previously approved 250-milligram dose.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care